非布索坦对痛风能有多大的疗效？

(Febuxostat) was developed in Japan in 2004, approved for marketing by European EMEA in 2008, approved for marketing by the US FDA in 2009, and approved for marketing by the China State Food and Drug Administration in 2013. How effective is Febuxostat (Febuxostat) for gout? Let's take a look.

Febuxostat (Febuxostat) is a commonly used drug for the treatment of gout. This drug has a good effect on controlling hyperuricemia, and it can also be taken for a long time. As long as the dosage of the drug is correct, it can basically avoid adverse effects on people's health. Animal experiments show that compared with allopurinol, febuxostat is 10 to 30 times more powerful.

The structure of Febuxostat (Febuxostat) is a non-purine analog, so it has selective inhibition on xanthine oxidase and has little effect on other enzymes involved in purine and pyrimidine metabolism. Allopurinol is a purine analogue, which can affect the activity of other enzymes involved in purine and pyrimidine metabolism in the body, and is prone to some adverse reactions.

The specificity of the inhibitory effect of Febuxostat (Febuxostat) can avoid these possible adverse reactions. Febuxostat (Febuxostat) is completely absorbed after oral administration, with a bioavailability of approximately 85%, a peak time of approximately 1 hour, and a half-life of 5 to 8 hours. Food and antacids have no significant effect on the absorption of febuxostat. Febuxostat (Febuxostat) can be used in combination with other drugs, such as colchicine (0.6 mg twice a day), certain non-steroidal anti-inflammatory drugs (naproxen, indomethacin, etc.), hydrochlorothiazide, warfarin, desimipramine, etc., without significant impact on the pharmacokinetics of the two, and no dose adjustment is required. However, it is currently not recommended to use febuxostat in combination with azathioprine and mercaptopurine because the latter two are metabolized by xanthine oxidase.

Research results show that long-term use of Febuxostat (Febuxostat) can maintain long-term blood uric acid at ≤6.0mg/dl in most patients. Mild to moderate impairment of renal function has no significant impact on the pharmacodynamics and pharmacokinetics of Febuxostat. Therefore, the uric acid-lowering effect of Febuxostat (Febuxostat) is no different from that of patients with normal renal function, and its safety is good. In short, (febuxostat) has a better uric acid-lowering effect than allopurinol without serious adverse reactions, and has good clinical application prospects.

Recommended related articles: